ES2732444T3 - Composiciones anestésicas volátiles que comprenden disolventes extractivos para anestesia regional y/o alivio del dolor - Google Patents

Composiciones anestésicas volátiles que comprenden disolventes extractivos para anestesia regional y/o alivio del dolor Download PDF

Info

Publication number
ES2732444T3
ES2732444T3 ES09703373T ES09703373T ES2732444T3 ES 2732444 T3 ES2732444 T3 ES 2732444T3 ES 09703373 T ES09703373 T ES 09703373T ES 09703373 T ES09703373 T ES 09703373T ES 2732444 T3 ES2732444 T3 ES 2732444T3
Authority
ES
Spain
Prior art keywords
solution
anesthetic
pain
isoflurane
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09703373T
Other languages
English (en)
Spanish (es)
Inventor
Christopher Capelli
Phillip Phan
Allen Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2732444T3 publication Critical patent/ES2732444T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09703373T 2008-01-22 2009-01-22 Composiciones anestésicas volátiles que comprenden disolventes extractivos para anestesia regional y/o alivio del dolor Active ES2732444T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2266508P 2008-01-22 2008-01-22
PCT/US2009/031706 WO2009094459A1 (en) 2008-01-22 2009-01-22 Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief

Publications (1)

Publication Number Publication Date
ES2732444T3 true ES2732444T3 (es) 2019-11-22

Family

ID=40456514

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09703373T Active ES2732444T3 (es) 2008-01-22 2009-01-22 Composiciones anestésicas volátiles que comprenden disolventes extractivos para anestesia regional y/o alivio del dolor

Country Status (10)

Country Link
US (3) US9675544B2 (https=)
EP (2) EP2244737B1 (https=)
JP (2) JP5789100B2 (https=)
CN (2) CN102014961B (https=)
AU (1) AU2009206390B2 (https=)
CA (1) CA2712731C (https=)
DK (1) DK2244737T3 (https=)
ES (1) ES2732444T3 (https=)
PL (1) PL2244737T3 (https=)
WO (1) WO2009094459A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
WO2010025505A1 (en) * 2008-09-04 2010-03-11 Phebra Pty Ltd Analgesia by transmucosal administration
CN109394689A (zh) 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
EP2723325A4 (en) 2011-06-24 2015-03-11 Vapogenix Inc NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
WO2013016511A1 (en) * 2011-07-27 2013-01-31 University Of Miami Stable liquid formulations of volatile gas anesthetics
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe
WO2017011865A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
WO2017011867A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
EP3325062A4 (en) 2015-07-20 2019-03-13 Medical Developments International Limited INHALER FOR INHALABLE LIQUIDS
US9554998B1 (en) 2015-08-04 2017-01-31 Damaso Fernandez Gines Composition of analgesic bioadhesive healing microspheres
AU2017325107B2 (en) 2016-09-06 2022-10-06 Medical Developments International Limited Inhaler device for inhalable liquids
CN115671084B (zh) * 2021-07-21 2023-09-15 四川大学华西医院 甲氧氟烷在制备抗肝包虫病的药物中的应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB445289A (en) * 1934-10-04 1936-04-06 Karl Merck manufacture of stabilised preparations of divinyl ether
US3097133A (en) * 1959-12-21 1963-07-09 Ici Ltd Anaesthetic 1: 1: 1: 3: 3: 3-hexafluoro-2-halopropane
BE786675A (fr) 1971-08-02 1973-01-25 Airco Inc Separation d'oxydes d'alkyle halogenes par distillation azeotropique.
US4109651A (en) 1975-11-19 1978-08-29 Steigerwald Allan M Anesthetic gas exhaust system
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4453951A (en) 1980-07-09 1984-06-12 General Electric Co. Process for the production of silicone carbide composite
SE8008962L (sv) 1980-12-18 1982-06-19 Erik Allan Lindkvist Anordning vid narkosmask
US4879062A (en) 1981-10-20 1989-11-07 Adamantech, Inc. Preparation of a gel having gas transporting capability
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4837163A (en) * 1987-10-02 1989-06-06 Tsuyoshi Ohnishi Simple blood test for diagnosing malignant hyperthermia
US4994025A (en) * 1989-08-29 1991-02-19 Baxter International Inc. Method of dissolving cholesterol-rich calculi with short chain halogenated organic solvents and cosolvents
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5677290A (en) 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5114714A (en) 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
DE4105972C2 (de) 1991-02-26 1999-06-02 Draegerwerk Ag Narkosemitteldosiervorrichtung
BE1005163A3 (fr) 1991-08-01 1993-05-11 Solvay Compositions contenant un ether fluore et utilisation de ces compositions.
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5230778A (en) 1992-05-01 1993-07-27 Gavlin Associates Purification of isoflurane by extractive distillation
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9308306D0 (en) 1993-04-22 1993-06-09 Univ Aberdeen Analgesic composition
GB9312578D0 (en) * 1993-06-18 1993-08-04 Isis Innovation Determining gas concentration
PT711289E (pt) 1993-07-30 2001-02-28 Delta Pharmaceuticals Inc Compostos piperazina utilizados em terapia
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5563153A (en) * 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5568910A (en) 1995-03-02 1996-10-29 Delmarva Laboratories, Inc. Anesthesia machine
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5861175A (en) * 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US20030212123A1 (en) 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
CA2288828A1 (en) 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US5976072A (en) 1998-01-29 1999-11-02 Johns Hopkins University Copa method for fiberoptic endotracheal intubation
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6830581B2 (en) 1999-02-09 2004-12-14 Innercool Therspies, Inc. Method and device for patient temperature control employing optimized rewarming
US6869440B2 (en) 1999-02-09 2005-03-22 Innercool Therapies, Inc. Method and apparatus for patient temperature control employing administration of anti-shivering agents
ES2267546T3 (es) * 1999-06-10 2007-03-16 Bridge Pharma, Inc. Agentes anestesicos dermicos.
US6706034B1 (en) 1999-12-30 2004-03-16 Advanced Cardiovascular Systems, Inc. Process for agent retention in biological tissues
US6669954B2 (en) 2000-01-25 2003-12-30 John R. Crison Controlled release of drugs
AU2001254625B2 (en) 2000-05-02 2006-02-02 Action Pharma A/S Use of alpha-MSH and EPO for preventing or treating ischemic conditions
US6770636B2 (en) 2000-08-18 2004-08-03 Boehringer Ingelheim Pharma Kg Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
MXPA04006572A (es) 2002-01-10 2005-11-04 Upjohn Co Terapia de combinacion antivirica.
US20030181426A1 (en) 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
AU2003219167A1 (en) 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
ES2346868T3 (es) 2002-08-10 2010-10-21 Yale University Antagonistas de receptor nogo.
CA2500310C (en) * 2002-10-11 2013-03-12 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
NZ542690A (en) 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US20030173287A1 (en) 2003-05-06 2003-09-18 Johnston Arthur W Filter devices and methods of use
EP1631234B1 (en) 2003-05-16 2011-09-14 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
BRPI0413426A (pt) 2003-08-07 2006-10-17 Biogen Idec Inc antagonistas de receptor novo
ATE395052T1 (de) 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE602004015142D1 (de) 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE365034T1 (de) * 2003-09-10 2007-07-15 Cristalia Prod Quimicos Farm Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether- verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
KR20060088885A (ko) 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법
US20070053963A1 (en) * 2004-01-13 2007-03-08 Hotchkiss Robert N Drug delivery to a joint
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2007070694A2 (en) * 2005-12-14 2007-06-21 Zars, Inc. Spray-on formulations and methods for dermal delivery of drugs
US8791163B2 (en) * 2006-01-13 2014-07-29 Mcgill University Melatonin ligands having antidepressant activity as well as sleep inducing properties
ES2535233T3 (es) * 2006-01-25 2015-05-06 Insys Therapeutics, Inc. Pulverización de fentanilo sublingual
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
EP2099408B1 (en) 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
CN109394689A (zh) 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法

Also Published As

Publication number Publication date
CN102014961A (zh) 2011-04-13
US20200253864A1 (en) 2020-08-13
US9675544B2 (en) 2017-06-13
JP5789100B2 (ja) 2015-10-07
CA2712731C (en) 2016-05-03
CA2712731A1 (en) 2009-07-30
WO2009094459A1 (en) 2009-07-30
AU2009206390B2 (en) 2014-10-30
EP2244737B1 (en) 2019-04-10
US10420720B2 (en) 2019-09-24
CN107661293A (zh) 2018-02-06
JP2011510091A (ja) 2011-03-31
JP2016026147A (ja) 2016-02-12
EP3581169A1 (en) 2019-12-18
AU2009206390A1 (en) 2009-07-30
DK2244737T3 (da) 2019-07-08
US20180015030A1 (en) 2018-01-18
PL2244737T3 (pl) 2020-05-18
US20110039944A1 (en) 2011-02-17
JP6033932B2 (ja) 2016-11-30
EP2244737A1 (en) 2010-11-03
CN102014961B (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
ES2732444T3 (es) Composiciones anestésicas volátiles que comprenden disolventes extractivos para anestesia regional y/o alivio del dolor
ES2765007T3 (es) Composiciones anestésicas volátiles y métodos de uso
DK2081562T3 (en) Method of administering volatile anesthetics for regional anesthesia and / or pain relief
AU2019201703B2 (en) Volatile anesthetic compositions and methods of use
AU2015200210B2 (en) Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief